Clinical trials
Completed Phase 1 Mood Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 6 |
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 3 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 21 |
| University Hospital, Basel, Switzerland | 6 |
| Luye Pharma Group Ltd. | 5 |
| BrainCells Inc. | 2 |
| Behman Hospital | 1 |
| Brigham and Women's Hospital | 1 |
| Laureate Institute for Brain Research, Inc. | 1 |
| Mary Fristad | 1 |
| Minneapolis Veterans Affairs Medical Center | 1 |
| National Institute of Mental Health (NIMH) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mood Disorders | 43 |
| Schizophrenia | 23 |
| Major Depressive Disorder | 8 |
| Mental Disorders | 8 |
| Psychotic Disorders | 7 |
| Substance-Related Disorders | 6 |
| Amphetamine-Related Disorders | 5 |
| Depressive Disorder | 5 |
| Depressive Disorder, Treatment-Resistant | 4 |
| Anxiety Disorders | 3 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.